Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2410051 | Vaccine | 2006 | 8 Pages |
Abstract
As polysialic acid (PSA), the capsule of Group B meningococcus (GBM) and Escherichia coli K1, is a component of mammalian glycopeptides, there is concern that vaccines against PSA could induce immunopathology. Purified PSA is not immunogenic; however, as a component of bacteria or bound to proteins, it induces protective antibodies. In this review, we did not unearth data indicating an association of IgG anti-PSA with immunopathology in experimental animals or humans. We found no increased incidence of autoimmunity from GBM infections in our review of the natural history/sequellae of Neisseria meningitis infections. Accordingly, we propose that clinical trials of PSA conjugate vaccines, be considered.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Daniel M. Stein, John Robbins, Mark A. Miller, Feng-Ying C. Lin, Rachel Schneerson,